Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells

被引:8
作者
Jeong, Yun Soo [1 ]
Lam, Thuy Giang [1 ]
Jeong, Seho [1 ]
Ahn, Sang-Gun [1 ]
机构
[1] Chosun Univ, Sch Dent, Dept Pathol, Gwangju 61452, South Korea
关键词
metformin; HL156A; multidrug resistance; HOXC6; angiogenesis; NF-KAPPA-B; PROTEIN-KINASE ACTIVATOR; BREAST-CANCER; DRUG-RESISTANCE; PHOSPHOINOSITIDE; 3-KINASE; MDR1; EXPRESSION; 2-ACETYLAMINOFLUORENE; METABOLISM; MECHANISMS; INDUCTION;
D O I
10.3390/ph13090218
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Multidrug resistance is a significant clinical crisis in cancer treatment and has been linked to the cellular expression of multidrug efflux transporters. The aim of this study was to examine the effects and mechanisms of the metformin derivative HL156A on human multidrug resistance (MDR) cancer cells. Here, HL156A significantly suppressed cell growth and colony formation through G2/M phase cell cycle arrest in MDR cancer cells. HL156A also reduced the wound closure rate and cell migration and induced caspase-3-dependent apoptosis. We found that HL156A inhibited the expression of MDR1 by inhibiting the HOXC6-mediated ERK1/2 signaling pathway and increased the sensitivity to paclitaxel or doxorubicin in MDR cells. Furthermore, HL156A significantly inhibited angiogenesis in a chicken chorioallantoic membrane (CAM) assay. These results suggest the potential of the metformin derivative HL156A as a candidate therapeutic modality for the treatment of human multidrug-resistant cancers.
引用
收藏
页码:1 / 15
页数:16
相关论文
共 44 条
[1]   Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells (vol 10, e0127841, 2015) [J].
Aldonza, Mark Borris Docdoc ;
Hong, Ji-Young ;
Bae, Song Yi ;
Song, Jayoung ;
Kim, Won Kyung ;
Oh, Jedo ;
Shin, Yoonho ;
Lee, Seung Ho ;
Lee, Sang Kook .
PLOS ONE, 2015, 10 (07)
[2]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[3]  
[Anonymous], 2014, SPE/AAPG/SEG Pore Pressure Workshop, DOI DOI 10.1155/2014/476974
[4]   Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy? [J].
Callaghan, Richard ;
Luk, Frederick ;
Bebawy, Mary .
DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) :623-631
[5]   Involvement of AP-1 and NF-κB in the Up-regulation of P-gp in Vinblastine Resistant Caco-2 Cells [J].
Chen, Qiuxia ;
Bian, Yicong ;
Zeng, Su .
DRUG METABOLISM AND PHARMACOKINETICS, 2014, 29 (02) :223-226
[6]   Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A) [J].
Choi, Junjeong ;
Lee, Ji-Hyun ;
Koh, Ilkyoo ;
Shim, Jin-Kyoung ;
Park, Junseong ;
Jeon, Jeong Yong ;
Yun, Mijin ;
Kim, Se Hoon ;
Yook, Jong In ;
Kim, Eui Hyun ;
Chang, Jong Hee ;
Kim, Sun Ho ;
Huh, Yong Min ;
Lee, Su Jae ;
Pollak, Michael ;
Kim, Pilnam ;
Kang, Seok-Gu ;
Cheong, Jae-Ho .
ONCOTARGET, 2016, 7 (40) :65643-65659
[7]  
CLYNES M, 1993, IN VITRO CELL DEV-AN, V29A, P171
[8]   Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer [J].
Davies, Gerald ;
Lobanova, Liubov ;
Dawicki, Wojciech ;
Groot, Gary ;
Gordon, John R. ;
Bowen, Matthew ;
Harkness, Troy ;
Arnason, Terra .
PLOS ONE, 2017, 12 (12)
[9]   Metformin: Multi-faceted protection against cancer [J].
Del Barco, Sonia ;
Vazquez-Martin, Alejandro ;
Cufi, Silvia ;
Oliveras-Ferraros, Cristina ;
Bosch-Barrera, Joaquim ;
Joven, Jorge ;
Martin-Castillo, Begona ;
Menendez, Javier A. .
ONCOTARGET, 2011, 2 (12) :896-917
[10]   2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-κB pathway [J].
Deng, L ;
Lin-Lee, YC ;
Claret, FX ;
Kuo, MT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (01) :413-420